Deucravacitinib Medicine 07 December 2021 Extended indication Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy Therapeutic value Possible added value for a subgroup Total cost Registration phase Clinical trials Product Active substance Deucravacitinib Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Skin diseases Extended indication Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer BMS Portfolio holder Mechanism of action Tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity New therapeutical formulation ATMP No Submission date October 2022 Expected Registration January 2023 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks De fabrikant verwacht indiening in oktober 2022 en registratie in januari 2023. Therapeutic value Current treatment options Bijvoorbeeld TNF-alfaremmers en Il12/23 remmers. Therapeutic value Possible added value for a subgroup This assessment does not indicate any potential inclusion in the package. Substantiation De veiligheid wordt als erg goed beschreven, vergelijkbaar met placebo. Deucravacitinib zal minder effectief zijn dan de biologicals, maar een meerwaarde hebben voor patiënten waarbij de biological niet aanslaat. Ook is het effectiever dan apremilast. Duration of treatment Frequency of administration 1 times a day Dosage per administration 6mg References NCT04772079 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Komt in principe beschikbaar voor alle patiënten met matige tot ernstige psoriasis, in Nederland zijn dat er circa 165.000. Als ook milde psoriasis onder de indicatie komt te vallen kan het beschikbaar zijn voor 500.000 patiënten. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks